8-K: Aptose Tuspetinib Exceeds AML Trial Expectations

Aptose Biosciences' tuspetinib, combined with standard care, achieved 100% complete remission rates in newly diagnosed AML patients at higher doses, surpassing expectations.

Summary

• Aptose Biosciences announced positive data from the Phase 1/2 TUSCANY trial of tuspetinib (TUS) in combination with venetoclax (VEN) and azacitidine (AZA) for newly diagnosed Acute Myeloid Leukemia (AML) patients ineligible for induction chemotherapy.
• The TUS+VEN+AZA triplet achieved complete remission (CR/CRh) responses in 6 out of 6 (100%) patients treated at higher dose levels (80 mg and 120 mg TUS), exceeding the 66% rate expected from VEN+AZA alone.
• Overall, 9 out of 10 (90%) patients across all dose cohorts achieved CR/CRh responses.
• 7 out of 8 (88%) CR/CRh responses were observed in FLT3 wildtype AML patients, representing 70% of the AML population.
• The therapy demonstrated MRD-negativity in 7 out of 9 (78%) responding patients by central flow cytometry.
• CR/CRh responses were achieved across diverse mutational subtypes, including TP53-mutated (2/2), RAS-mutated (1/1), and FLT3-ITD (2/2) AML patients, indicating a mutation-agnostic therapy.
• The TUS+VEN+AZA combination was well tolerated with no dose-limiting toxicities (DLTs), differentiation syndrome, QTc prolongation, prolonged myelosuppression, CPK elevation, or treatment-related deaths reported at any dose level to date.
• Dosing has now commenced at the 160 mg TUS dose level.

Sentiment

Score: 9

Explanation: The TUSCANY trial data for tuspetinib in combination with standard of care for newly diagnosed AML patients showed exceptional efficacy, including 100% CR/CRh rates at higher doses, significantly surpassing the expected benchmark. The therapy also demonstrated a strong safety profile and mutation-agnostic activity, indicating a highly promising development.

Positives

• 100% CR/CRh responses in 6/6 patients at higher TUS dose levels (80 mg and 120 mg), significantly exceeding the 66% rate expected from VEN+AZA alone.
• Overall 90% CR/CRh responses (9/10 patients) across all dose cohorts.
• High CR/CRh rate (88%, 7/8 patients) in FLT3 wildtype AML, which represents 70% of the AML population.
• Achieved MRD-negativity in 78% (7/9) of responding patients by central flow cytometry.
• Effective across diverse mutational subtypes, including unmutated FLT3, FLT3-ITD, NPM1c, biallelic TP53 with complex karyotype, RAS, and myelodysplasia related mutations, indicating a truly mutation-agnostic therapy.
• Well-tolerated with no DLTs, differentiation syndrome, QTc prolongation, prolonged myelosuppression after remission in Cycle 1, CPK elevation, or treatment-related deaths.
• TUS can be safely added to VEN+AZA without needing to reduce the dose of these standard-of-care drugs.

Risks

• Ability to obtain the capital required for research and operations and to continue as a going concern.
• Inherent risks in early-stage drug development, including demonstrating efficacy.
• Development time/cost and the regulatory approval process.
• Progress of clinical trials.
• Ability to find and enter into agreements with potential partners.
• Ability to attract and retain key personnel.
• Changing market conditions.
• Inability of new manufacturers to produce acceptable batches of GMP in sufficient quantities.
• Unexpected manufacturing defects.
• Other risks detailed from time-to-time in ongoing quarterly filings, annual information forms, annual reports, and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Future Outlook

The TUSCANY trial aims to develop the tuspetinib-based triplet therapy (TUS+VEN+AZA) as an improved, active, durable, and well-tolerated frontline therapy for newly diagnosed AML patients across diverse populations. Dosing is currently ongoing at the 160 mg TUS level, with anticipated enrollment of 18-24 patients by the end of 2025. The company plans to release data as it becomes available.

Management Comments

• "We have observed that TUS can be safely added to a backbone VEN+AZA without needing to reduce the dose of these standard-of-care drugs."
• "The activity we have observed with the TUS triplet in the first 10 patients has exceeded our expectations with 9 achieving complete remissions and 7 demonstrating MRD-negativity by central flow cytometry."
• "In addition, these remissions are happening in diverse genetic subtypes including those with unmutated FLT3, FLT3-ITD, NPM1c, biallelic TP53 with complex karyotype, RAS, or myelodysplasia related mutations, making this a truly mutation agnostic therapy." (Rafael Bejar, M.D., Ph.D., Chief Medical Officer of Aptose)

Industry Context

The development of TUS+VEN+AZA as a mutation-agnostic frontline therapy addresses a significant unmet medical need in AML, particularly for patients ineligible for induction chemotherapy. By demonstrating efficacy across diverse genetic subtypes and a favorable safety profile when combined with the standard of care (VEN+AZA), Aptose is positioning tuspetinib to potentially improve outcomes for a broad AML patient population, which is a key trend in precision oncology.

Comparison to Industry Standards

• The TUS+VEN+AZA combination achieved CR/CRh responses in 100% (6/6) of patients treated at higher dose levels (80 mg and 120 mg TUS), exceeding the 66% rate expected from VEN+AZA alone.

Stakeholder Impact

• Shareholders: Positive clinical trial results are highly likely to increase investor confidence and potentially the company's stock value.
• AML Patients: The development of a safe, well-tolerated, and mutation-agnostic frontline therapy offers a promising new treatment option, especially for those ineligible for induction chemotherapy.
• Medical Community: The data provides new insights into combination therapies for AML and supports the potential of tuspetinib.
• Employees: Positive clinical progress can boost morale and reinforce the company's strategic direction.

Next Steps

• Dosing with 160 mg TUS is now ongoing in the TUSCANY trial.
• Anticipated enrollment of 18-24 patients in the TUSCANY trial by the end of 2025.
• Data will be released as it becomes available.

Key Dates

Recommendation

The clinical trial results for tuspetinib are exceptionally strong, demonstrating 100% complete remission rates at higher doses, significantly exceeding the expected efficacy of the standard-of-care alone. The therapy is also well-tolerated and effective across diverse genetic subtypes, addressing a broad patient population. This data suggests a high probability of clinical success and market potential, making it a compelling investment opportunity for a seasoned investor.

Keywords

Tuspetinib, AML, Acute Myeloid Leukemia, TUSCANY trial, Oncology, Clinical-stage, Precision medicine, Venetoclax, Azacitidine, FLT3 wildtype, TP53-mutated, RAS-mutated, FLT3-ITD, MRD-negativity, Hematology, Biotechnology